Intelligent Bio Solutions preliminary Q4 revenue up ~16% sequentially and YoY, driven by cartridge sales

INTELLIGENT BIO SOLUTIONS INC.

2025-FY EPS reported -$2.00 revenue$3,052,532

Preliminary Q4 FY2025 revenue growth of ~16% sequentially and year-over-year, driven by higher-margin cartridge sales and account growth.
Submitted FDA 510(k) application for opiate test system (codeine) to support planned U.S. market entry.
Completed multilingual system upgrades and launched localized websites to strengthen global adoption across Europe, Middle East, and Latin America.
Full-year FY2025 results and Form 10-K expected to be filed during the week of August 11, 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.